生物活性 | |||
---|---|---|---|
描述 | AZ194 is a pioneering, orally administered inhibitor that disrupts the CRMP2-Ubc9 interaction and inhibits NaV1.7 with an IC50 of 1.2 µM. It prevents the SUMOylation of CRMP2, effectively decreasing the amount of NaV1.7 expressed on the cell surface and provides antinociceptive effects[1]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.76mL 0.35mL 0.18mL |
8.81mL 1.76mL 0.88mL |
17.62mL 3.52mL 1.76mL |
参考文献 |
---|